logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HR+/HER2- advanced breast cancer: palbociclib-letrozole is safe, effective in Japanese patients

Phase 2 trial finds PFS at 1 year was 76%.